Seminars in Hematology
Volume 46, Supplement 3 , Pages S22-S26, April 2009

Understanding the Role of Mutations in Therapeutic Decision Making for Chronic Myeloid Leukemia

  • Elias Jabbour

      Affiliations

    • Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX
    • Corresponding Author InformationAddress correspondence to Elias Jabbour, MD, Assistant Professor of Medicine, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030
    • ,
  • Simona Soverini

      Affiliations

    • Molecular Biology Unit, Department of Hematology and Medical Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Editorial support was provided by Daniel Hutta, PhD, and Michael Mandola, PhD (Health Interactions) on behalf of Novartis Oncology.

 STATEMENT OF CONFLICT OF INTEREST: Dr Jabbour is on the Speakers Bureau for Novartis Pharmaceuticals Corp. Dr Soverini has no relationships with the supplement sponsor to disclose.

PII: S0037-1963(09)00020-1

doi:10.1053/j.seminhematol.2009.01.009

Seminars in Hematology
Volume 46, Supplement 3 , Pages S22-S26, April 2009

Article Tools

* Image Usage & Resolution